Genzyme and Isis - Billion-dollar deals

Who: Genzyme
With: Isis Pharmaceuticals
What: $1.9 billion deal

Scoop: Genzyme agreed to fork over up to $1.9 billion for rights to Isis Pharmaceutical's flagship program mipomersen, a cholesterol drug candidate. The company reportedly survived a bidding war for the drug that involved 10 companies. Mipomersen blocks a gene that opens the gate to cholesterol in the blood. It's now about to enter Phase III trials after posting some impressive data for lowering bad cholesterol.

Related Articles:
Genzyme wins Isis pact with $1.9B bid
Genzyme on buyouts: Thanks but no thanks
Is Carl Icahn out to buy Genzyme?
More good news from RNAi company Isis
Isis gains from big RNAi deal